By Pierre Bertrand

Merck KGaA said Friday that it has discontinued a Phase 2 trial for berzosertib in combination with topotecan in patients with relapsed, platinum-resistant small-cell lung cancer.

The German pharmaceuticals and chemicals company said that, following an interim analysis, the study was discontinued due to low probability of meeting the pre-defined objective of the trial.

"SCLC remains a difficult-to-treat disease, with minimal advances in the past 20 years," Merck said, adding that it will continue external studies exploring berzosertib in additional combinations and clinical settings.

Write to Pierre Bertrand at pierre.bertrand@wsj.com

(END) Dow Jones Newswires

June 03, 2022 10:06 ET (14:06 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Merck KGaA (PK) 차트를 더 보려면 여기를 클릭.
Merck KGaA (PK) (USOTC:MKKGY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Merck KGaA (PK) 차트를 더 보려면 여기를 클릭.